Vancouver’s Victory Square Health has been granted approval by the Brazilian Health Regulatory Agency to commence marketing, sales and distribution for its Safetest ELISA Covid-19 antibody test.
Victory Square Health acquired Brazilian Covid19 test developers Safetest in June.
The Brazilian approval comes on the heels of Safetest being granted permission by the Food & Drug Administration (FDA) in the United States to commence marketing, sales and distribution under emergency use authorization last month.
With 4,500,000 confirmed cases and 127,000 deaths as of September 8th, Brazil has the third highest number of cases in the world with a population of 210 million.
“Our mission is to help the global community curb the spread of Covid-19 by delivering the best tests in the market,” said Felipe Peixoto, CEO of Victory Square Health. “This approval from Brazil now breaks down many barriers for the Company to export its Safetest Elisa products to Mercosur Countries (Argentina, Paraguay, Uruguay, and Venezuela),” said Peixoto. Approval from the government of Brazil allows for export to qualifying Mercosur countries.
The antibody data provided by the Safetest Covid-19 IgM/IgG Elisa test kit covers both immunoglobulins type M (IgM) and G (IgG). When IgM antibodies are present, they can indicate that a patient has an active or recent infection with SARS-CoV-2. When IgG antibodies are present, it indicates a past infection and exposure.
The company is currently engaging various industries including but not limited to retail, hospitality, pharmaceutical, correctional facilities, casinos, sport, border services, education, transportation, military, government, and more. Safetest ELISA Covid-19TM tests will be available in next coming weeks.